If You Invested in Generate Biomedicines (GENB)
Looking for the live price? See the GENB quote & overviewWhat $1,000 or $10,000 in GENB Would Be Worth Today
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Feb 27, 2026 |
|---|---|---|---|---|
| $1,000 | — | — | — | $1,243 +24% |
| $10,000 | — | — | — | $12,427 +24% |
Based on real historical closing prices through the latest market close. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for GENB$1,000 Investment Over Time
GENB vs S&P 500Year-by-Year Returns
GENB annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2026 | $12.65 | $15.72 | +24.3% | +24.3% |
About Generate Biomedicines
Pharmaceutical Preparations · NASDAQ
Generate Biomedicines, Inc. develops protein therapeutics using a generative biology platform that applies machine learning to drug discovery and development. The company is a clinical-stage biotechnology issuer focused on programming novel protein medicines across therapeutic areas and modalities. Its common stock trades on Nasdaq under the symbol GENB.
The company reports a single operating segment engaged in generative biology. Its Generate Platform is designed to create and optimize protein therapeutic candidates by using computational methods to generate medicines across multiple modalities. Generate's operating model centers on advancing internally developed and partnered programs from platform discovery into clinical development.
Pipeline and therapeutic focus
Generate Biomedicines' named product candidates include GB-0895, an anti-TSLP program being developed for respiratory diseases including severe asthma and COPD; GB-4362, an MMAE neutralizer in oncology that has received FDA Fast Track designation; and GB-5267, a MUC16 armored CAR T program developed in collaboration with Roswell Park Comprehensive Cancer Center. These programs reflect the company's use of generative biology across different therapeutic modalities, including antibody-based and cellular therapy approaches.
The company's business is centered on research and development rather than commercial product sales. As a clinical-stage biotechnology company, its recurring activities include platform development, preclinical and clinical program advancement, regulatory interactions, collaboration work, and financing of research and development operations.
Public-company structure
Generate Biomedicines became a public company through an initial public offering of common stock. In connection with the IPO, the company adopted an amended and restated certificate of incorporation and amended and restated bylaws that define its public-company governance framework, authorized capital structure, stockholder meeting procedures, and board authority to issue undesignated preferred stock. The company is based in Somerville, Massachusetts.
Frequently Asked Questions
Generate Biomedicines investment returns
How much would $1,000 invested in Generate Biomedicines be worth today?
Limited historical data is available for GENB. The stock has been trading since 2026-02-27.
Has Generate Biomedicines outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare GENB performance over available time periods.
What is Generate Biomedicines's average annual return?
Your Privacy is Protected
This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.
For informational and educational purposes only — not investment advice.
